20 Headache Medicine, v.3, n.1, p.13-20, Jan./Feb./Mar. 2012
24. van der Mooren MJ, Kenemans P. Postmenopausal hormone
therapy: impact on menopause-related symptoms, chronic
disease and quality of life. Drugs. 2004;64(8):821-36.
25. Hunter M. The Women's Health Questionnarie: a measure of
mid-aged women's perceptions of their emotional and physical
health. Psychol Health.1992;7(1):45-54.
26. Silva-Filho CR, Baracat EC, Haidar MA, Ferraz MB. Climacteric
symptoms and quality of life: validity of women's health
questionnaire. Rev Saude Publica. 2005;39(3):333-9.
27. Snaith RP, Bridge GWK, Hamilton M. The Leeds's scales for the
self-assessment of anxiety and depression.Br J Psychiatry. 1976;
128:156-65.
28. Hamilton M. The assessment of anxiety states by rating. Br J
Med Psychol. 1959;32(1):50-5.
29. Hamilton M. Development of a rating scale for primary depressive
illness. Br J Soc Clin Psychol. 1967;6(4):278-96.
30. Hunter MS. Psychological and somatic experience of the menopause:
a prospective study [corrected]. Psychosom Med. 1990; 52(3):
357-67. Erratum in Psychosom Med 1990;52(4):410.
31. Slaven L, Lee C. A Cross-sectional Survey of Menopausal Status,
Symptoms and Psychological Distress in a Community Sample
of Australian Women. J Health Psychol. 1998;3(1):117-23.
32. Wiklund I, Berg G, Hammar M, Karlberg J, Lingren R, Sandin NK. Long-
term effect of transdermal hormonal therapy on aspects of quality
of life in postmenopausal women. Maturitas .1992;14(3): 225-36.
33. Shin H, Shin HS. Measurement of quality of life in menopausal
women: A systematic review. West J Nurs Res published online
25 March 2011. [internet] Disponível em: http://wjn.sagepub.
com/content/early/2011/03/30/0193945911402848
34. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden
of migraine in the United States: disability and economic costs.
Arch Intern Med. 1999;159:813-8.
35. National Center for Health Statistics. Vital and Health Statistics
of the United States. Dept of Health, Education, and Welfare.
Advance data. Hyattsville, MD: National Center for Health
Statistics, 1979. PHS Publication No. 53. Disponível em: http://
www.cdc.gov/nchs/products/pubs/pubd/nvsr/53/53-prehtm
36. Celentano DD, Stewart WF, Lipton RB, Reed ML. Medication use
and disability among migraineurs: a national probability sample.
Headache. 1992;32(5):223-8.
37. Fry J. Profiles of Disease. Edinburgh: Churchill Livingstone,
1996:45-56.
38. Bigal ME, Bordini CA, Speciali JG. Headache in an emergency
room. São Paulo Med J. 2000;118:58-62.
39. Lipton RB, Stewart WF, Scher AI. Epidemiology and economic impact
of migraine. Curr Med Res Opin. 2001;17(suppl 1):4S-12S.
40. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M.
Prevalence and burden of migraine in the United States: data from
the American Migraine Study II. Headache. 2001; 41(7):646-57.
41. Dahlöf C, Bouchard J, Cortelli P, et al. A multinational investigation
of the impact of subcutaneous sumatriptan. II. Health-related
quality of life. Pharmacoeconomics. 1997;11(suppl 1):24 -34
42. Santanello NC, Polis AB, Hartmaier SL, Kramer MS, Block GA,
Silberstein SD. Improvement in migraine-specific quality of life in
a clinical trial of rizatriptan. Cephalalgia. 1997;17(8):867- 2.
43. American Headache Society, 2007 MIDAS (The Migraine
Disability Assessment Test). [Internet] Disponível em: http://
www.americanheadachesociety.org/
44. Stewart WF, Lipton RB, Dowson AJ, Sawyer J. 2001. Development
and testing of the Migraine Disability Assessment (MIDAS)
Questionnaire to assess headache-related disability. Neurology.
56:S20-S28.
45. Winner P, Ricalde O, Le Force B, Saper J, Margul B. A double
blind study of sub-cutaneous dihydroergotamine vs subcutaneous
sumatriptan in the treatment of acute migraine. Arch Neurol.
1996;53(2):180-4. Comment in Arch Neurol. 1996;53(12):
1215-6.
46. Martin VT, Behbehani M. Ovarian hormones and migraine
headache: understanding mechanisms and pathogenesis--part
2. Headache. 2006; 46(3):365-86.
47. Brandes JL. The influence of estrogen on migraine: a systematic
review. JAMA. 2006; 295(15):1824-30.
48. Lipton RB, Stewart WF. Migraine in the United States: a review of
epidemiology and health care use. Neurology. 1993; 43(6 Suppl
3):S6-10.
49. Waters WE, O'Connor PJ. Epidemiology of headache and migraine
in women. J Neurol Neurosurg Psychiatry. 1971;34(2):148-53.
50. Melhado EM, Maciel JA Jr, Guerreiro CA. Headache during
gestation: evaluation of 1101 women. Can J Neurol Sci. 2007;
34(2):187-92.
51. Kornstein SG, Parker AJ. Menstrual migraines: Etiology,
treatment, and relationship to premenstrual syndrome. Curr Opin
Obstet Gynecol. 1997;9(3):154-9.
52. Neri I, Granella F, Nappi R, Manzoni GC, Facchinetti F,
Genazzani AR. Characteristics of headache at menopause: a
clinico-epidemiologic study. Maturitas 1993; 17(1):31-7.
53. Mattsson P. Hormonal factors in migraine: a population-based
study of women aged 40 to 74 years. Headache. 2003;43(1):
27-35.
54. Ciciarelli MC. Cefaléia e ciclo hormonal. In Cefaléias (Speciali,
JG. & Silva, WF. Editores), 2002.
55. Wang SJ, Fuh JL, Lu SR, Juang KD, Wang PH. Migraine prevalence
during menopausal transition. Headache. 2003; 43(5):470-8.
Comment in Headache. 2004;44(1):106; author reply 106.
56. Calhoun AH. Migraine and menopause. Headache 2004;
44(1):106; author reply 106. Comment on Headache. 2003
May;43(5):470-8.
57. Somerville BW. Estrogen-withdrawal migraine. II. Attempted
prophylaxis by continuous estradiol administration. Neurology.
1975;25(3):245-50.
58. Somerville BW. Estrogen-withdrawal migraine. I. Duration of
exposure required and attempted prophylaxis by premenstrual
estrogen administration. Neurology. 1975; 25(3):239-44.
59. Misakian AL, Langer RD, Bensenor IM, Cook NR, Manson JE,
Buring JE, et al. Postmenopausal hormone therapy and migraine
headache. J Womens Health (Larchmt) 2003; 12(10):1027-36.
Correspondência
Sidraiton Sálvio Alves de Melo FilhoSidraiton Sálvio Alves de Melo Filho
Sidraiton Sálvio Alves de Melo FilhoSidraiton Sálvio Alves de Melo Filho
Sidraiton Sálvio Alves de Melo Filho
Rua Mamanguape, 455/103 – Boa Viagem
51020-250 – Recife, PE, Brasil
e-mail: sidraitonfilho@hotmail.com
MELO FILHO SS, VALENÇA MM
Recebido: 8/1/2012
Aceito: 28/2/2012